A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

NCT06077877 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: GSK4524101
DRUG: Niraparib

Sponsor

GlaxoSmithKline